Literature DB >> 17401592

Economic aspects of the new Spanish laws on pharmaceutical preparations.

Fernando Antoñanzas1, Juan Oliva, Mariola Pinillos, Carmelo Juàrez.   

Abstract

In this article, we provide readers with a summary of the main economic features of the recently approved Spanish law regarding pharmaceutical preparations entitled the Law of Guarantees and Rational Use of Pharmaceuticals and Health Products (Law 29/2006 of July 26th). We review information on pricing, reference pricing, promotion of generic drugs, public reimbursement, patients' contributions, and penalties. Other aspects of minor economic relevance such as the information on prices shown in the packs and the transparency on the results of clinical trials irrespective of whether these are positive or not, are not addressed in this paper. We conclude with some observations on the new horizons opened up by this new legal framework. We have not included any detailed references to the new law; we merely wish to comment on certain aspects of its application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401592     DOI: 10.1007/s10198-007-0050-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  6 in total

1.  The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.

Authors:  Iván Moreno-Torres; Jaume Puig-Junoy; Josep M Raya
Journal:  Eur J Health Econ       Date:  2010-09-01

2.  Assessing the impact of global price interdependencies.

Authors:  Anke Richter
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  The challenge of colorectal cancer prevention in Spain.

Authors:  Julio Lopez-Bastida; Begoña Bellas-Beceiro; Enrique Quintero-Carrión
Journal:  Eur J Health Econ       Date:  2010-01

4.  Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis.

Authors:  Ferrán Catalá-López; Adolfo Alonso-Arroyo; Rafael Aleixandre-Benavent; Manuel Ridao; Máxima Bolaños; Anna García-Altés; Gabriel Sanfélix-Gimeno; Salvador Peiró
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

Review 5.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

6.  Using multicriteria decision analysis during drug development to predict reimbursement decisions.

Authors:  Paul Williams; Josephine Mauskopf; Jake Lebiecki; Anne Kilburg
Journal:  J Mark Access Health Policy       Date:  2014-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.